All articles tagged with #quest diagnostics
Apple is testing a completely redesigned Health app in the iOS 27.2 beta, featuring new Insights and Longevity tabs. The update introduces a 'Health Age' metric based on activity and sleep, along with on-device fitness assessments. While the app is available in the beta, full features like personalized guidance and lab ordering will launch later this year, requiring an Apple Watch for optimal use.
Apple has announced a comprehensive redesign of the Health app for iOS 27, featuring AI-driven insights, a new Longevity tab, and integration with Quest Diagnostics for blood testing. The update leverages enhanced sensors in the Apple Watch Series 12 and Ultra 4 to provide more accurate heart rate and HRV data, aiming to compete with rivals like WHOOP and Oura.
Quest Diagnostics has launched AD-Detect, the first direct-to-consumer blood test that detects abnormal levels of beta amyloid, a protein associated with Alzheimer's disease. Priced at $399, the test allows individuals aged 18 and older with mild memory loss or a family history of Alzheimer's to assess their risk for the disease. If the test is positive, users will be contacted by a doctor to discuss next steps. While the test has not undergone FDA review, it can be prescribed by a healthcare provider.
Quest Diagnostics has released the first blood test for consumer purchase that can assess the risk of developing Alzheimer's disease. The AD-Detect Test for Alzheimer's Disease costs $399 and uses plasma from a single blood draw to evaluate levels of amyloid beta proteins, which are linked to the progression of Alzheimer's disease. The test aims to detect early signs associated with the risk of developing the disease and make Alzheimer's disease risk assessment more accessible. Test results will be available on a secure patient portal.
Quest Diagnostics has launched the first blood-based biomarker test, called AD-Detect, to assess the risk of developing Alzheimer's disease. The test evaluates the ratio of two peptides of amyloid beta in plasma, which helps assess the risk based on the brain protein's contribution to the disease. With emerging treatments and growing recognition of non-pharmacological interventions, there is increasing acceptance of blood tests for early detection. The number of Americans diagnosed with Alzheimer's is expected to reach 14 million by 2060.
Positive marijuana urine tests after workplace accidents among the general U.S. workforce hit 7.3% in 2022, the highest level in 25 years, according to a Quest Diagnostics analysis. The higher percentage had a correspondence with the move by some states to make usage of marijuana legal. Quest Diagnostics found that the percentage of people in the general U.S. workforce that tested positive for marijuana came in at 4.3% in 2022, marking an increase from the prior year. The analysis also looked at how positive worker marijuana tests differed in states based on the legality status of the substance.
A study by Quest Diagnostics has found that marijuana use among US workers reached "historic" highs in 2022, with 4.3% of over 6 million general workforce urine tests being positive for cannabis, up from 3.9% in 2021. The industries that saw the greatest increase in positivity rates over the past five years were hospitality and food services, retail, and finance/insurance. The study also found that 7.3% of workers who had suffered a workplace injury tested positive for marijuana in 2022, marking the highest positivity rate in 25 years.